Moira A Rynn

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials
    Moira A Rynn
    New York State Psychiatric Institute, 1051 Riverside Drive, Unit 74, New York, NY 10032, USA
    Am J Psychiatry 164:290-300. 2007
  2. ncbi Advances in pharmacotherapy for pediatric anxiety disorders
    Moira Rynn
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Depress Anxiety 28:76-87. 2011
  3. ncbi Paroxetine in the treatment of generalised anxiety disorder
    Steven H Snyderman
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 5:1799-806. 2004
  4. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
  5. ncbi Generalized anxiety disorder: acute and chronic treatment
    Moira A Rynn
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    CNS Spectr 9:716-23. 2004
  6. ncbi Open-label pilot study of ziprasidone for refractory generalized anxiety disorder
    Steven H Snyderman
    J Clin Psychopharmacol 25:497-9. 2005
  7. ncbi The psychometric properties of the MASC in a pediatric psychiatric sample
    Moira A Rynn
    Department of Psychiatry, Mood and Anxiety Disorders Program, Center for Psychotherapy Research, Suite 670, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104 3309, USA
    J Anxiety Disord 20:139-57. 2006
  8. ncbi Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment
    Sarosh Khalid-Khan
    Department of Psychiatry, Mood and Anxiety Disorders Clinic, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Paediatr Drugs 9:227-37. 2007

Collaborators

Detail Information

Publications8

  1. ncbi Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials
    Moira A Rynn
    New York State Psychiatric Institute, 1051 Riverside Drive, Unit 74, New York, NY 10032, USA
    Am J Psychiatry 164:290-300. 2007
    ..The authors evaluated the efficacy, safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized anxiety disorder...
  2. ncbi Advances in pharmacotherapy for pediatric anxiety disorders
    Moira Rynn
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Depress Anxiety 28:76-87. 2011
    ..Novel compounds that affect the glutamate system will be discussed...
  3. ncbi Paroxetine in the treatment of generalised anxiety disorder
    Steven H Snyderman
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 5:1799-806. 2004
    ....
  4. ncbi Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    ..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...
  5. ncbi Generalized anxiety disorder: acute and chronic treatment
    Moira A Rynn
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    CNS Spectr 9:716-23. 2004
    ..There is still an urgent need to explore treatment combinations and duration strategies in the management of patients suffering with GAD...
  6. ncbi Open-label pilot study of ziprasidone for refractory generalized anxiety disorder
    Steven H Snyderman
    J Clin Psychopharmacol 25:497-9. 2005
  7. ncbi The psychometric properties of the MASC in a pediatric psychiatric sample
    Moira A Rynn
    Department of Psychiatry, Mood and Anxiety Disorders Program, Center for Psychotherapy Research, Suite 670, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104 3309, USA
    J Anxiety Disord 20:139-57. 2006
    ..The MASC is a clinically useful measure to discriminate between anxious and depressed pediatric patients. Limitations due to the highly selective sample are noted...
  8. ncbi Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment
    Sarosh Khalid-Khan
    Department of Psychiatry, Mood and Anxiety Disorders Clinic, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Paediatr Drugs 9:227-37. 2007
    ..There is some evidence that the use of combination therapy, both pharmacology and psychosocial treatment, is beneficial in the management of pediatric SOC...